ODDO : Memory: What if we were on the eve of a super cycle?

Memory prices have risen by 15% m-o-m and by ~30% since the start of 2025. This reflects a tight supply situation, with demand for AI stronger than expected. Memory inventories are also at an all-time low, paving the way for a super cycle in 2026, driven by AI but also by the integration of Edge AI in smartphones/PCs. A semis market at ~+15-20% in 2026 is a credible scenario in this context. In our coverage, this should first benefit ASML, VAT, Siltronic, ASMi and SUSS (Outperform vs Neutral), f...

ODDO : Mémoire : Et si nous étions à l’aube d’un ‘supercycle’ ?

ODDO BHF SECURITIES LARGE CAPS MORNING NEWS 10/10/2025

ODDO BHF SECURITIES LARGE CAPS MORNING NEWS 10/10/2025

Elia Group : High voltage growth path back on track

Seeing that the construction of the Belgian energy island is now progressing well, that the new CEO is acting stricter on cost control, that the demand for new bonds of Elia Transmission Belgium and 50Hertz has remained high at attractive yields, that the German regulator is expected to improve the regulatory rates framework for the next regulatory period, and that the investment fits perfectly in Europe’s ambitions to become less dependent on Russia, we today reiterate our Outperform recommenda...

Morning Notes : AALB NA, HEIA NA, TESB BB, UMI BB

: AALB NA, HEIA NA, TESB BB, UMI BB

Aalberts Macro outlook calls for reality check, 2026 recovery less pro...

We have revisited our scenario for Aalberts in light of persistent political instability in France and the continued publication of uninspiring leading indicators. With the company's substantial exposure to both the French and German markets, and its reliance on automotive and machine-building as key end markets, we have revised our 2026 organic growth forecast downward to 1.6%. We expect consensus to follow in the coming months. Despite the (historically) cheap valuation, we downgrade the stock...

Benelux Morning Notes

Aalberts: Preview - difficult YoY comp in Semi division. Arcadis: Returning to organic growth in 3Q25. Shell plc: A bit ahead of expectations. Vopak: No many changes in 3Q, solid story continues

Morning Notes : CPINV BB, CMBT BB, NN NA, MAAT FP

: CPINV BB, CMBT BB, NN NA, MAAT FP

MaaT Pharma Safety board recommends MaaT033 phase 2b continues as plan...

MaaT announced that the independent data safety monitoring board (DSMB) has completed the second pre-planned safety interim analysis of the ongoing randomised controlled phase 2b (PHOEBUS) trial of MaaT033 (microbiome therapy, oral capsule) in patients undergoing an allogeneic hematopoietic stem cell transplantation (allo-HSCT), and recommended that the study continue as planned. There were no safety concerns and no excessive mortality related to MaaT033 as of today. The upcoming routine DSMB re...

Aalberts/Model update/BUY

Ahead of Aalberts 3Q25 trading update (due 23 October) we update our financial 2025-27F forecasts. Aalberts interim results arrived slightly below our estimates, and end market conditions in our view have not improved in 3Q25. We lower our FY25 adjusted EBITA margin estimate to 13.5%, now in line with Aalberts' recent outlook. Our FY26 forecasts now include the acquisition Grand Venture Technologies as we expect the take-over to finalise towards the end of this year (delisting date at or around ...

Life Sciences Conference 25 Sep 2025

KBC Securities will host its annual life sciences conference on 25 September in Brussels. The event will include 14 exciting companies, both public and private, from the BeNeLux ecosystem and beyond. In this conference note, we provide an overview of the attending companies, as well as an outlook on KBC Securities' life sciences broader coverage.

MaaT Pharma 1H25 results confirm timelines, runway to end Feb 2026

MaaT reported 1H25 results with € 2.4m in revenues from the early access program (1H24: € 1.7m) for MaaT013 in aGvHD, which points to increased demand for the product ahead of a potential EU approval in 2H26. Pipeline timelines were reiterated and we look forward to the final data from the phase 3 trial for MaaT013 in aGvHD for confirmation of the initial survival data reported in January 2025 (54% at 1-year). Beyond aGvHD, data from the phase 2 trial of MaaT013 in combination with ICI in metast...

Morning Notes : PNL NA, UCB BB, MAAT FP, DEME BB, SYENS BB

: PNL NA, UCB BB, MAAT FP, DEME BB, SYENS BB

Daimler Truck : Sustainability Weekly 8 - 12 September 2025

Last week, we published a report in which we propose ideas on the theme of sustainable sovereignty. Technip Energies signed an agreement to acquire the Advanced Materials & Catalysts business of Ecovyst Inc, a global leader in specialty catalysts and advanced materials. The IEA is expected to reintroduce its slow transition scenario, ‘Current Policies’, in its next World Energy Outlook, probably under pressure from the Trump administration. German Chancellor Merz has hinted at a slowdown in the ...

Daimler Truck : Sustainability Weekly 8 – 12 septembre 2025

La semaine passée, nous avons publié une étude où nous proposons des idées pour la thématique de la souveraineté durable. Technip a signé un accord en vue d'acquérir l'activité Advanced Materials & Catalysts d'Ecovyst Inc, leader mondial des catalyseurs spéciaux et des matériaux avancés. L'AIE devrait réintroduire son scénario de transition lente « Current Policies » dans son prochain World Energy Outlook, probablement sous la pression de l'administration Trump. Le chancelier allemand Merz a lai...

Morning Notes : OCW BB, EVS BB, IMMO BB, XIOR BB, ECMPA NA

: OCW BB, EVS BB, IMMO BB, XIOR BB, ECMPA NA

Benelux Morning Notes

Azelis: Highlights ING Benelux Conference London. Barco: Highlights ING Benelux Conference London. Kinepolis: Highlights ING Benelux Conference London. Melexis: Highlights ING Benelux Conference London. ABN AMRO: Dutch State reducing stake to 20%. ASML: x Mistral, a bet on A.I.. Kinepolis: Cineplex August 2025 box office revenue at 87% of 2019 level, down 27% YoY